CureVac Clause Samples
CureVac. Subject to CureVac’s obligations as set forth in paras (ii) and (iii) of the Disclosure Letter, CureVac shall work exclusively with GSK on the Development, Manufacture and Commercialization of mRNA-Based vaccine and mRNA-Based antibody products targeting the SARS-CoV-2 Pathogen, and CureVac shall not, and shall procure that its Affiliates will not, develop, manufacture or commercialize, solely or with a Third Party, any mRNA-Based vaccine or mRNA-Based antibody targeting the SARS-CoV-2 Pathogen other than: (i) a COVID Product Developed and/or Commercialized under this Agreement, and (ii) the First-Gen COVID Vaccine Products, subject to Section 3.3.7. This Section 2.3.2 and the covenants set forth herein shall not apply to activities of any Third Party (or such Third Party’s Affiliates) that becomes an Affiliate of CureVac solely as a result of a Change of Control in CureVac, provided that such activities are performed without using the CureVac mRNA technology described in the CureVac Know-How or within the scope of specification of the CureVac Patent Rights.
CureVac. Subject to CureVac's obligations as set forth in items (ii) and (iii) of the Disclosure Letter, CureVac shall work exclusively with GSK on the Development, Manufacture and Commercialization of Products targeting a Collaboration Pathogens, and CureVac shall not, and shall procure that its Affiliates will not, develop, manufacture or commercialize, solely or with a Third Party, any prophylactic and/or therapeutic mRNA-Based vaccine or mRNA-Based antibody targeting a Collaboration Pathogen other than a Product Developed and/or Commercialized under this Agreement. This Section 2.3.2 and the covenants set forth herein shall not apply to activities of any Third Party (or such Third Party's Affiliates) that becomes an Affiliate of CureVac solely as a result of a Change of Control in CureVac, provided that such activities are performed without using the CureVac mRNA technology described in the CureVac Know-How or within the scope of specification of the CureVac Patent Rights.
CureVac. Overview: Founded in 2000 35, CureVac is a NASDAQ- listed36 biopharmaceutical company headquartered in Germany37. Its revenue in the same nine-month period increased by 304% from €10.6 million in 2019 to €42.8 million during the first nine months of 202038. 25 European Pharmaceutical Review, “AstraZeneca”, ▇▇▇▇▇://▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇/organisations/astrazeneca/ 26 AstraZeneca, “Contact Information”, ▇▇▇▇▇://▇▇▇.▇▇▇▇▇▇▇▇▇▇▇.▇▇▇/investor-relations/annual-reports/annual-report-2016/contact-information.html 27 AstraZeneca, “FAQs”, ▇▇▇▇▇://▇▇▇.▇▇▇▇▇▇▇▇▇▇▇.▇▇▇/investor-relations/faqs.html 28 AstraZeneca, “What science can do - AstraZeneca Annual Report and Form 20-F Information 2020”, ▇▇▇▇▇://▇▇▇.▇▇▇▇▇▇▇▇▇▇▇.▇▇▇/content/dam/az/Investor_Relations/annual-report-2020/pdf/AstraZeneca_AR_2020.pdf 29 ▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇, “AstraZeneca COVID-19 Vaccine (AZD1222)”, January 27, 2021, ▇▇▇▇▇://▇▇▇.▇▇▇.▇▇▇/vaccines/acip/meetings/downloads/slides-2021-01/02-COVID-▇▇▇▇▇▇▇▇▇.pdf 30 European Medicines Agency, “Vaxzevria (previously COVID-19 Vaccine AstraZeneca)”, 31 Reuters, “AstraZeneca agrees to supply Europe with 400 million doses of COVID-19 vaccine”, June 13, 2020, ▇▇▇▇▇://▇▇▇.▇▇▇▇▇▇▇.▇▇▇/article/us-health-coronavirus-vaccines-idUSKBN23K0HW 32 ▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇, “The Serum Institute of India”, December 8, 2020, Fierce Pharma, ▇▇▇▇▇://▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇/special-report/top-10-manufacturers-fight-against-covid-19-serum-institute-india 33 ▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇, “AstraZeneca hopes warmer storage needs for COVID-19 vaccine will be an advantage against mRNA competitors”, November 23, 2020, Fierce Pharma, ▇▇▇▇▇://▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇/manufacturing/astrazeneca-hopes-warmer-storage-needs-for-covid-19-vaccine-will-be-advantage-against 34 ▇▇▇▇▇▇ ▇▇▇▇▇, et al. Who funded the research behind the Oxford-AstraZeneca COVID-19 vaccine? Approximating the funding to the University of Oxford for the research and development of the ChAdOx vaccine technology. medRxIV, 10 April 2021. Available online: ▇▇▇▇▇://▇▇▇.▇▇▇/10.1101/2021.04.08.21255103 35 CureVac, “History, How it all began”, ▇▇▇▇▇://▇▇▇.▇▇▇▇▇▇▇.▇▇▇/en/about-us/historie-rework/ 36 ▇▇▇▇▇▇ ▇▇▇▇▇▇, “▇▇▇▇▇▇▇ says well on track to request vaccine approval as planned”, May 5, 2021, Reuters, ▇▇▇▇▇://▇▇▇.▇▇▇▇▇▇▇.▇▇▇/business/healthcare-pharmaceuticals/curevac-says-well-track-request-vaccine-approval-planned-2021-05-05/ 37 CureVac, “CVnCoV, CureVac’s mRNA-based vaccine candidate against COVID-19”, ▇▇▇▇▇://▇▇▇.▇▇▇▇▇▇▇.▇▇▇/en/covid-19/#timel...